New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund
Two of the three companies vying for an additional share of England’s CDK4/6 inhibitor market have now secured reimbursement for the use of their products in combination with fulvestrant for advanced breast cancer.
You may also be interested in...
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
The SMC has given the all clear to funding for Lilly’s Verzenios for breast cancer, Richter’s Reagila for schizophrenia, and MSD’s Keytruda for melanoma. However, it rejected Alliance’s Xonvea for sickness in pregnancy because the evidence on benefits and cost effectiveness did not stack up.
Novartis is having a harder time than Eli Lilly at getting health technology assessment body NICE to agree to make its breast cancer CDK4/6 inhibitor in combination with fulvestrant available on the National Health Service.